- Home
- MPB vs ABVX Comparison
MPB vs ABVX Comparison
Compare MPB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- ABVX
- Stock Information
- Founded
- MPB 1868
- ABVX 2013
- Country
- MPB United States
- ABVX France
- Employees
- MPB N/A
- ABVX N/A
- Industry
- MPB Major Banks
- ABVX
- Sector
- MPB Finance
- ABVX
- Exchange
- MPB Nasdaq
- ABVX Nasdaq
- Market Cap
- MPB 628.8M
- ABVX 5.3B
- IPO Year
- MPB N/A
- ABVX N/A
- Fundamental
- Price
- MPB $30.14
- ABVX $81.03
- Analyst Decision
- MPB Buy
- ABVX Buy
- Analyst Count
- MPB 2
- ABVX 7
- Target Price
- MPB $34.50
- ABVX $74.86
- AVG Volume (30 Days)
- MPB 85.7K
- ABVX 1.1M
- Earning Date
- MPB 10-22-2025
- ABVX 08-11-2025
- Dividend Yield
- MPB 2.65%
- ABVX N/A
- EPS Growth
- MPB N/A
- ABVX N/A
- EPS
- MPB 2.30
- ABVX N/A
- Revenue
- MPB $191,454,000.00
- ABVX $11,444,012.00
- Revenue This Year
- MPB $24.57
- ABVX $25.23
- Revenue Next Year
- MPB $12.23
- ABVX N/A
- P/E Ratio
- MPB $13.10
- ABVX N/A
- Revenue Growth
- MPB 13.34
- ABVX 128.98
- 52 Week Low
- MPB $22.50
- ABVX $4.77
- 52 Week High
- MPB $33.87
- ABVX $82.13
- Technical
- Relative Strength Index (RSI)
- MPB 67.30
- ABVX 82.18
- Support Level
- MPB $29.50
- ABVX $78.00
- Resistance Level
- MPB $30.42
- ABVX $78.49
- Average True Range (ATR)
- MPB 0.54
- ABVX 2.95
- MACD
- MPB 0.23
- ABVX -0.99
- Stochastic Oscillator
- MPB 90.64
- ABVX 92.66
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.